Lee Sang Chul, Jin Hyun Seung, Joo Young, Kim Yong Chul, Moon Jee Youn
Department of Anesthesiology and Pain Medicine, Seoul National University Hospital Department of Anesthesiology and Pain Medicine, Samsung Medical Center Department of Anesthesiology and Pain Medicine, Integrated Cancer Management Center, Seoul National University Cancer Hospital, Seoul, Republic of Korea.
Medicine (Baltimore). 2017 Mar;96(9):e6149. doi: 10.1097/MD.0000000000006149.
Nutraceuticals containing cis-9-cetylmyristoleate (CMO) are used to improve knee pain despite the lack of placebo-controlled studies in humans. The aim of the study was to explore the minimal effective dose of CMO for relieving knee joint pain.
Twenty-eight subjects with mild degree arthritic knee joint pain were randomized into 4 groups; groups A, B, and C that contained 100%, 80%, and 62.4% of fatty acid component with 12.5% of CMO, and control group D (starch 100%). The pain intensity, functional disability, and the Patient Global Impression of Change (PGIC) were assessed for a 12-week ingestion period.
Compared to group D (n = 6), there were significant differences in pain score in group A (n = 7, P = 0.005) and group C (n = 7, P = 0.012), but not significant in group B (n = 6, P = 0.180). Western Ontario and McMaster Universities Arthritis (WOMAC) score decreased significantly in groups A and C. The PGIC was positive in the majority (>50%) in groups A, B, and C, whereas negative in 83.3% in group D (control).
CMO is effective in alleviating knee pain in persons with mild degree arthritis of the knee joint, at an effective dose of 62.4%.
尽管缺乏针对人类的安慰剂对照研究，但含有顺式-9-十六碳烯酸肉豆蔻酯（CMO）的营养保健品仍被用于改善膝关节疼痛。本研究的目的是探索缓解膝关节疼痛的CMO最小有效剂量。
28名患有轻度关节炎膝关节疼痛的受试者被随机分为4组；A组、B组和C组含有脂肪酸成分的100%、80%和62.4%，CMO含量为12.5%，对照组D（100%淀粉）。在为期12周的摄入期内评估疼痛强度、功能障碍和患者整体变化印象（PGIC）。
与D组（n = 6）相比，A组（n = 7，P = 0.005）和C组（n = 7，P = 0.012）的疼痛评分有显著差异，但B组（n = 6，P = 0.180）无显著差异。A组和C组的西安大略和麦克马斯特大学关节炎指数（WOMAC）评分显著降低。A组、B组和C组中大多数（>50%）的PGIC为阳性，而D组（对照组）中83.3%为阴性。
CMO对缓解膝关节轻度关节炎患者的膝关节疼痛有效，有效剂量为62.4%。
Zotero 插件